Joyson Karakunnel

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Scott Antonia, Sarah B. Goldberg, Ani Sarkis Balmanoukian et al. · The Lancet Oncology · 2016 · 589 citations · Full text

Phase 1B, Medicine, Immunology +7

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Lacey Padrón, Deena M. Maurer, Mark H. O’Hara et al. · Nature Medicine · 2022 · 316 citations · Full text

Randomized Phase 2, Pancreatic Cancer, Gastrointestinal Oncology +13

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary et al. · The Lancet Oncology · 2020 · 286 citations

Phase 1B, Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma +7

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

Don L. Gibbons, Laura Q.M. Chow, Dongwook Kim et al. · Journal of Thoracic Oncology · 2016 · 109 citations · Full text

Immunology, Immune Checkpoint Inhibitor, Egfr Mutant Nsclc +5

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

Kathryn C. Arbour, Jarushka Naidoo, Keith E. Steele et al. · PLoS ONE · 2017 · 66 citations · Full text